Search
Oprelvekin
go.drugbank.com/drugs/DB00038ApprovedInvestigationalWithdrawnOprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. … With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long.
Synonyms: IL-11Terbutaline
go.drugbank.com/drugs/DB00871ApprovedInvestigational[A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088] … Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s and early 1970s.
Mixtures: BRICANYL EX, BİCANA 1,5 MG/5 ML + 66,5 MG/5 ML ŞURUP, 100 MLCategories: Adrenergic beta-2 Receptor Agonists, Selective Beta 2-adrenergic AgonistsHuman botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115ApprovedInfant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.
Categories: Human Immunoglobulin GSynonyms: Botulism immune globulin IV human, Human botulinum neurotoxin A/B immune globulinFencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnFencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. … It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose.
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalThis allows less frequent dosing and a lower daily dose with improvement in tolerability [A32043]. … It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844] [A32046].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesLevomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigationalLevomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. … [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011]
Synonyms: CYCLOPROPANECARBOXAMIDE, 2-(AMINOMETHYL)-N,N-DIETHYL-1-PHENYL-, (1S,2R)-Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: SUNVEPRA® 100MG CÁPSULAS BLANDASOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigationalIn patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity is lower. … Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients.
Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesSynonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigational[A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized